The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome
Open accessAbstract
Objective: The objective of this study was to report the benefit of a therapeutic approach consisting of intravenous (IV) continuous anakinra (recombinant human interleukin‐1 receptor antagonist) infusions in treating severely ill adult patients with secondary hemophagocytic lymphohistiocytosis or macrophage activation syndrome (MAS). Methods: A retrospective chart review of five patients treated at Regions Hospital from 2016 to 2019 was conducted. Demographic, clinical, and laboratory characteristics and outcomes were recorded. Results: Continuous IV anakinra infusions up to 2400 mg/d resulted in rapid serologic, then clinical response in 4 of 5 severely ill patients who were refractory to all other therapies, including subcutaneous anakinra. Subsequently, 3 of 5 patients have been maintained on anakinra or canakinumab, with no recurrence of MAS. Conclusion: Continuous infusion of IV anakinra may result in rapid serologic and subsequent clinical improvement in adult patients with MAS. This method for treating cytokine storm should be considered in the current COVID‐19 pandemic in the subgroup of patients with severe disease who have a cytokine storm presentation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001402 · Cited by 867
The Immunology of Macrophage Activation Syndrome
Crayne, C. B., Albeituni, S., Nichols, K. E., & Cron, R. Q. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00119 · Cited by 633
Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis
Eloseily, E. M., Weiser, P., Crayne, C. B., Haines, H., Mannion, M. L., Stoll, M. L., Beukelman, T., Atkinson, T. P., & Cron, R. Q. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41103 · Cited by 282
Cited by
Jamilloux, Y., Henry, T., Belot, A., Viel, S., Fauter, M., El Jammal, T., Walzer, T., François, B., & Sève, P. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102567 · Cited by 658
IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines
Tahtinen, S., Tong, A.-J., Himmels, P., Oh, J., Paler-Martinez, A., Kim, L., Wichner, S., Oei, Y., McCarron, M. J., Freund, E. C., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01160-y · Cited by 535
Pharmaco-Immunomodulatory Therapy in COVID-19
Rizk, J. G., Kalantar-Zadeh, K., Mehra, M. R., Lavie, C. J., Rizk, Y., & Forthal, D. N. (2020) · Drugs · doi:10.1007/s40265-020-01367-z · Cited by 288
Inflammation in Coronary Microvascular Dysfunction
Sagris, M., Theofilis, P., Antonopoulos, A. S., Oikonomou, E., Paschaliori, C., Galiatsatos, N., Tsioufis, K., & Tousoulis, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413471 · Cited by 115
A rationale for targeting the P2X7 receptor in Coronavirus disease 19
Di Virgilio, F., Tang, Y., Sarti, A. C., & Rossato, M. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15138 · Cited by 71
Metadata
- Authors
- Monteagudo, L. A., Boothby, A., & Gertner, E.
- Venue
- ACR Open Rheumatology
- Publisher
- Wiley
- Published
- 2020-04-21
- Volume
- 2
- Issue
- 5
- Pages
- 276-282
- ISSN
- 2578-5745 (ISSN-L)
- OpenAlex
- W3014967682
- Cited by
- 183
- References
- 3
- FWCI
- 22.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.